News

Chaperone Therapeutics Partners With ALS Therapy Development Institute for ALS Research

The ALS Therapy Development Institute has just signed a research partnership with Chaperone Therapeutics, Inc., a company that specializes in treatments that address protein misfolding and neuronal cell loss, the underlying causes of neurodegenerative disease. The new partners will be working on potential treatments for amyotrophic lateral sclerosis (ALS), in order to facilitate preclinical development…

UMMS Researchers Make Progress in ALS Research

It has already been a year since the ALS Ice Bucket Challenge took the internet by storm, causing countless American households, celebrities and public figures to show support for ongoing efforts to find a cure for amyotrophic lateral sclerosis. In the wake of the viral campaign, a team of scientists…

Neuralstem Wins Patent Infringment Case on Stem Cell Technology

Biopharmaceutical company, Neuralstem, Inc. has just announced the US District Court in Maryland has decided to dismiss StemCell, Inc.’s previously filed patent infringement case with prejudice in StemCells, Inc. v. Neuralstem, Inc. in favor of Neuralstem, on July 22, 2015. Neuralstem is most known for its proprietary stem cell technology. It has…